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ORIGINAL RESEARCH
Simulated Hypergravity Activates 
Hemostasis in Healthy Volunteers
Ulrich Limper , MD*; Tobias Ahnert, MD*; Marc Maegele, MD; Matthias Froehlich, MD; Marijke Grau, MSc;  
Peter Gauger, MSc; Ursula Bauerfeind, MD; Klaus Görlinger , MD; Bernhard Pötzsch, MD; Jens Jordan , MD
BACKGROUND: Hypergravity may promote human hemostasis thereby increasing thrombotic risk. Future touristic suborbital 
spaceflight will expose older individuals with chronic medical conditions, who are at much higher thromboembolic risk com-
pared with professional astronauts, to hypergravity. Therefore, we tested the impact of hypergravity on hemostasis in healthy 
volunteers undergoing centrifugation.
METHODS AND RESULTS: We studied 20 healthy seated men before and after 15 minutes under 3 Gz hypergravity on a long-arm 
centrifuge. We obtained blood samples for hemostasis testing before, immediately after, and 30 minutes after centrifugation. Tests 
included viscoelastic thromboelastometry, platelet impedance aggregometry, endothelial activation markers, blood rheology test-
ing, microparticle analyses, and clotting factor analysis. Exposure to hypergravity reduced plasma volume by 12.5% (P=0.002) 
and increased the red blood cell aggregation index (P<0.05). With hypergravity, thrombelastographic clotting time of native blood 
shortened from 719±117 seconds to 628±89 seconds (P=0.038) and platetet reactivity increased (P=0.045). Hypergravity short-
ened partial thromboplastin time from 28 (26–29) seconds to 25 (24–28) seconds (P<0.001) and increased the activity of co-
agulation factors (eg, factor VIII 117 [93–134] versus 151 [133–175] %, P<0.001). Tissue factor concentration was 188±95 pg/
mL before and 298±136 pg/mL after hypergravity exposure (P=0.023). Antithrombin (P=0.005), thrombin-antithrombin complex 
(P<0.001), plasmin-alpha2-antiplasmin complex (0.002), tissue-plasminogen activatior (P<0.001), and plasminogen activator in-
hibitor-1 (P=0.002) increased with centrifugation. Statistical adjustment for plasma volume attenuated changes in coagulation.
CONCLUSIONS: Hypergravity triggers low-level hemostasis activation through endothelial cell activation, increased viscoe-
lasticity, and augmented platelet reactivity, albeit partly counteracted through endogenous coagulation inhibitors release. 
Hemoconcentration may contribute to the response.
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The gravitational challenge imposed on the human cardiovascular system during standing on Earth elicits venous stasis, hemoconcentration, ortho-
static hypercoagulability, and vascular endothelial ac-
tivation.1 Moreover, orthostatic presyncope induces 
blood hypercoagulability2 lasting at least 20 minutes.3 
The response may be exacerbated following bed-
rest immobilization4 and in patients recovering from 
strokes.5 In addition to classical components of the 
coagulation cascade, red blood cells appear to con-
tribute to hemostasis and thrombosis. Red blood cell 
aggregation and deformability, which affect blood vis-
cosity, respond to gravity, exercise, temperature, and 
hypoxia.6 Fighter pilots and astronauts during take 
off and landing are exposed to much greater gravity 
forces compared with standing on Earth. Presyncopal 
symptoms or overt syncope may ensue. We hypoth-
esized that hypergravity may elicit hypercoagubility. 
Indeed, cell and animal studies revealed platelet and 
endothelial cell activation along with excess red blood 
cell aggregation with hypergravity.7,8 Furthermore, se-
rious thromboembolic conditions have been reported 
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during hypergravity centrifuge training and during roll-
ercoster rides.9,10 However, studies on the effects of 
hypergravity on human blood rheology and hemosta-
sis are scarce. The issue is relevant for professional 
astronauts, particularly during deep space exploration 
and for recreational astronauts.11 The latter group will 
comprise individuals with preexisting thromboembolic 
risk factors. Therefore, we tested effects of exposure 
to a 15-minute cycle of 3 Gz hypergravity stress on the 
hemostasic system in healthy men.
METHODS
The data that support the findings of this study are 
available from the corresponding author upon reason-
able request.
Participants
We included 20 healthy, nonsmoking, men (33±8 years, 
1.83±0.06  cm, 82±6  kg). None had a history of 
thromboembolic events or orthostatic intolerance. 
They did not ingest platelet inhibiting drugs for at least 
14 days prior to the study. Each participant success-
fully passed a flight medical examination before par-
ticipation. We obtained written informed consent prior 
to inclusion, and the study was approved by the eth-
ics committee of the North Rhine Medical Association 
(protocol No. 2013060). The participant shown on 
Figure  1 provided written informed consent for this 
publication. All research was performed in accordance 
with the Declaration of Helsinki.
Experimental Hypergravity
We conducted the study at the Deutsches Zentrum 
für Luft- und Raumfahrt Institute of Aerospace 
Medicine in Cologne, Germany. Experimental hy-
pergravity challenge was executed using a human 
long-arm centrifuge. Centrifuge runs were performed 
between 8:00 am and 11:00 am. Ambient temperature 
and humidity during centrifuge runs were held at 26°C 
and 56%, respectively. Heart rate and beat-to-beat 
CLINICAL PERSPECTIVE
What Is New?
• Altered gravity may pose an increased throm-
botic risk on astronauts; we report the first 
systematic physiological data on the effects of 
hypergravity on healthy human hemostasis.
• We observed red blood cells, platelets, plas-
matic coagulation, and endothelium to be af-
fected by hypergravity.
• Hypergravity transiently elicits a subtle procoag-
ulatory phenotype in healthy people, which may 
be partly mediated through hemoconcentration.
What Are the Clinical Implications?
• These findings should prompt clinical studies 
on hemostasic alterations and the thrombotic 
risk of hypergravity exposure in aviators, pro-
fessional astronauts, as well as individuals with 
chronic medical conditions applying for a tour-
istic spaceflight.
Nonstandard Abbreviations and Acronyms
FV coagulation factor V
FVIII coagulation factor VIII
FXIII coagulation factor XIII
Gz  force of weight in head-to-foot 
direction
y at dIsc min  shear rate balancing red blood 
cell aggregation and 
disaggregation y at dIsc min
Figure 1. Evolution of the estimated arterial pressure at the 
level of the feet during centrifugation.
A, A representative participant sitting inside the centrifuge 
gondola with the right arm fixated at the level of the heart for 
beat-to-beat blood pressure measurements. The white arrow 
indicates the hydrostatic column of interest for arterial pressure 
estimates at the level of the feet. B, Graphs indicate averaged 
diastolic (shaded columns) and systolic (black columns) pressure 
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finger blood pressure at heart level were continu-
ously monitored (Finometer MIDI Device; Finapres 
Medical Systems, Amsterdam, The Netherlands) and 
stored using BIOPAC-software (BIOPAC Systems 
Inc., Goleta, CA, USA). Arterial pressure at the level 
of the feet was subsequently estimated by adding a 
hydrostatic pressure component to the systolic arte-
rial pressure at the heart level (Figure 1). The pressure 
of the hydrostatic column from the heart to the foot (P) 
was calculated as P=h×g×ρ. h is the height of the level 
of the heart above the ground (0.6 m), g is the accel-
eration acting on the participant inside the centrifuge 
gondola resulting from 3g centrifugal acceleration and 
1g Earth gravity (3.16g), and ρ is the density of the 
blood (1.0621 g/cm3).12
Participants were placed in sitting position in 
a fully closed swing-out cabin attached to the 5 m 
long centrifuge arm (Figure  1A). During centrifuga-
tion, the G-load acted strictly caudally. Centrifuge 
runs included a 15-minute plateau at 3 Gz (22 rpm) 
and a 0.1  g/s acceleration and decelaration phase 
(Figure  2A). For baseline recordings, participants 
remained seated for 30  minutes inside the centri-
fuge gondola. Blood samples were drawn from an-
tecubital veins through puncture without tourniquet 
after the 30-minute baseline phase had elapsed 
(pre), immediately after the centrifuge run (post), and 
after 30 minutes ambulation in the centrifuge facility 
(post+30) (Figure 2A).
Red Blood Cell Aggregation
We calculated relative blood and plasma volume 
changes from hemoglobin and hematocrit measure-
ments.13 For red blood cell rheology measurements, 
sampled blood was anticoagulated using sodium 
heparin vacutainer. Measured red blood cell param-
eters (Sysmex Digitana KX-21N, Sysmex, Switzerland) 
included red blood cell number, hemoglobin concen-
tration, hematocrit, and mean cellular hemoglobin 
concentration, a marker for intracellular viscosity. For 
red blood cell aggregation measurements, we ad-
justed hematocrit to 40% and fully oxygenated sam-
ples for 15 minutes with a Roller Mixer (Karl Hecht KG, 
Germany). We measured aggregation index (%) and 
shear rate balancing red blood cell aggregation and 
disaggregation (y at dIsc min [1/s]) using a laser-as-
sisted optical rotational cell analyzer (RR Mechatronics, 
Zwaag, The Netherlands).14 We assessed red blood 
cell deformability by ektacytometry using the same de-
vice.15 The samples were sheared in a Couette system 
at 9 consecutive shear stresses ranging from 0.3 and 
50 Pa. We calculated the ratio of maximum deformabil-
ity and shear stress required for one-half of maximum 
deformability with lower values representing higher red 
blood cell deformability.
Functional Viscoelastic Assays and 
Platelet Function
We conducted whole point-of-care coagulation test-
ing within 30  minutes after each blood draw from 
citrated blood (ROTEM; Tem International GmbH, 
Munich, Germany) and from hirudine blood using 
an impendance aggregometer (Multiplate; Verum 
Diagnostica GmbH, Munich, Germany). We performed 
native, extrinsic, intrinsic, and under platelet inhibition 
Figure 2. Effects of 15 minutes of 3 Gz hypergravity on the 
cardiovascular system, red blood cell function, and cell-
based blood coagulation.
A, Black triangles are medians±interquartile range and black 
dots are means±SD indicating heart rate (HR) and mean 
arterial pressure (MAP) responses with respect to gravity load 
shown by black graph. One-minute intervals were averaged 
at pre and post and 5-minute intervals were averaged during 
centrifugation. Syringes indicate blood draws (pre, post, 
post+30); (B) black columns indicate medians of relative plasma 
changes±interquartile range at post and post+30 compared to 
pre; (C) black columns show mean±SD aggregation index of 
red blood cells before, after and 30 minutes after hypergravity 
exposure; (D) black columns give median±interquartile range 
of the area under the curve (AUC) of platelet activation with 
arachidonic acid before, after, and 30 minutes after hypergravity; 
(E) black columns give median±interquartile range of the counts 
of microparticles presenting externalized phosphatidylserine 
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activated viscoelastic tests. Moreover, we determined 
coagulation time, clot formation time, and maximum 
clot firmness. We analyzed platelet function by imped-
ance aggregometry after stimulation with adenosine 
diphosphate, arachidonic acid, thrombin receptor acti-
vating peptide-6, ristocetin, or collagen.
Extended Coagulation Assays
We centrifuged blood samples for subsequent labo-
ratory coagulation assays 20  minutes at 1550g and 
20°C and stored them at −80°C. Flow cytometry with 
cell-specific markers was used to determine the mi-
croparticle quantity and their cellular origin. We ana-
lyzed microparticles after samples had undergone 
ultracentrifugation. We added cell-specific antibod-
ies for thrombocytes to 30 μL plasma and incubated 
20  minutes at room temperature, as described pre-
viously.16 For the determination of platelet origin, we 
used fluorescein isothiocyanate labelled anti-CD42b 
against glycoprotein Ib and peridinin chlorophyll 
Cy5.5-labelled anti-CD61 against glycorpotein IIIa. For 
microparticles derived from activated platelets, we ap-
plied phyocerythrin labelled anti-CD62p against p-se-
lectin. Additionally, allophycocyanin labelled annexin V 
served as marker of procoagulant phosphatidylserine.
We analyzed the concentration of fibrinogen, the 
activity of coagulation factors V, VIII, and XIII, the 
concentration of soluble tissue factor, coagulation 
inhibitiors (protein C activity, antithrombin activity, 
thrombomodulin concentration), activation markers 
thrombin-antithrombin III complex, d-dimer concen-
tration, prothrombin fragment F1+2 concentration, 
plasminogen activator inhibitor concentration), plas-
min-alpha2-antiplasmin complex concentration, and 
tissue plasminogen activator concentration at the 
Institutes of Hematology of the University Hospital Bonn 
and the Cologne-Merheim Medical Center (Germany). 
The results of proteins examined by concentration 
measures were corrected for changes in plasma vol-
ume to indicate a hemoconcentration-driven effect on 
the concentrations of large circulating molecules.17
Statistical Analysis
A Shapiro-Wilk test was used to test for normality. 
Normally and nonnormally distributed data are ex-
pressed as means± SD and median±interquartile 
range (IQR), respectively. We compared groups (blood 
samples: pre, post, post+30; cardiovascular data: 
phases 1–5) by 1-way repeated measures analysis of 
variance with Tukey’s post hoc test. Data with non-
normal distribution were analyzed with Wilcoxon and 
Friedman test, respectively. Individual differences be-
tween pre and post measurements of data sets with 
high interindividual variance were plotted as waterfall 
charts for a visual test for clinically relevant extreme 
subgroups. We then tested for significant subgroup 
effects by quantile regression. Calculations were per-
formed with IBM SPSS Statistics version 26. A value 
for P<0.05 was considered as statistically significant.
RESULTS
Hypergravity Elicits Cardiovascular 
Stress, Plasma Volume Loss, and 
Hemoconcentration
Eighteen out of 20 participants completed the entire 
centrifuge run. We excluded 2 participants from the 
analysis because centrifugation had to be terminated 
prematurely because of severe motion sickness. During 
centrifugation, heart rate increased from 83 (IQR, 76–
95) to 119  bpm (IQR, 101–137) (P<0.001) and mean 
arterial pressure at the level of the heart from 108±17 
to 129±15 mm Hg (P<0.001) (Figure 1A). The estimated 
average of the mean arterial pressure at the level of the 
feet rose from 251 mm Hg in 1 Gz to 277 mm Hg in 3 Gz. 
Hypergravity elicited substantial reduction in plasma vol-
ume and hemoconcentration (Figure 2B and Table 1).
Hypergravity Worsens Red Blood Cell 
Rheology
Both aggregation index and minimal shear rate needed 
to dissociate red blood cell aggregates (y at dIsc min) in-
creased after hypergravity compared with baseline (both 
P<0.05) (Figure 2C, Table 1). A subset of 6 out of the 20 
participants (33%, 77th percentile) showed an above av-
erage increase of y at dIsc min to 728±8 s−1. However red 
blood cell deformability was unaffected by hypergravity.
Platelet and Endothelial Cell Activation 
With Hypergravity
Circulating platelet and endothelial microparticle con-
centrations increased after centrifugation. Ex vivo 
platelet function testing revealed temporal changes 
in aggregability after exposure to hypergravity. 
Arachidonic acid induced platelet function increased in 
overall strength from 87 (IQR, 79–113) to 94 (IQR, 81–
111) area under the curve units (P=0.045) (Figure 2D, 
Table 1). In addition, microparticle counts, character-
ized by annexin surface marker, displayed a tempo-
ral increase during hypergravity (P=0.028) (Figure 2E, 
Table 1). The finding is consistent with in vivo platelet 
and endothelial cell activation.
Integrated Blood Coagulability Is 
Augmented With Hypergravity
The thrombelastographic clotting time of native blood 
decreased from 719±117 seconds to 628±89 seconds 
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blood coagulability. Remarkably, despite normalization 
of cardiovascular regulation, plasma volume, and hemo-
concentration, the response was sustained after 30 min-
utes of recovery (Figure 3B). Compared with baseline, 
hypergravity altered further viscoelastic properties of 
blood clots (Table 2).
Hypergravity Augments Plasmatic 
Procoagulation Pathways
Concentration measures corrected for plasma vol-
ume are shown by italicized numbers in the tables 
and by grey dotted graphs in the figures. D-dimer 
Table 1. Hypergravity-Induced Changes of the Cellular Hemostatic System
Pre Post Post+30 P Value
Plasma volume change (%) … −12.5 (−14.5 to −8.9) −0.2 (−2.9 to 2.8) 0.002
Blood volume change (%) … −6.9 (−7.8 to −6.1) −0.1 (−1.4 to 1.9) 0.003
Blood count
Hematocrit, % 43.2±3.1 46.3±3.6 43.5±3.2 <0.001
Hemoglobin, g/dL 15.4±1.0 16.4±1.2 15.4±1.1 <0.001
Red blood cells, ×106/µL 5.0±0.4 5.3±0.4 5.0±0.4 <0.001
Mean corpuscular hemoglobin concentration, g/dL 35.6±0.4 35.5±0.3 35.4±0.4 0.015
Platelets, ×109/L 219±35 242±35 213±29 0.023
228±34† 214±31† 0.431†
White blood cells, ×109/L 5.1±1.2 6.5±2.0 5.0±1.3 0.006
6.1±1.9† 5.0±1.3† 0.045*,†
Blood rheology
Red blood cell aggregation index, % 62.4±5.9 67.7±6.5 60.4±6.8 0.001
Shear rate balancing red blood cell aggregation and 
disaggregation (y at dIsc min [1/s])
75.8±18.7 320.0±349.7 119.7±172.0 0.003
Red blood cell deformability (SS1/2:EImax) 3.69±0.4 3.68±0.6 3.80±0.6 0.668
Platelet function
ADP induced, velocity 16 (14–21) 18 (14–22) 17 (12–21) 0.022
ADP, induced aggregation 163±28 172±31 163±32 0.622
ADP induced, AUC (U) 81±18 90±21 82±22 0.387
Arachidonic acid induced, velocity 19 (17–22) 21 (19–24) 18 (15–21) 0.021
Arachidonic acid induced, aggregation 188 (149–219) 199 (162–218) 175 (143–200) 0.182
Arachidonic acid induced, AUC (U) 91 (79–113) 105 (81–111) 86 (75–104) 0.045
Thrombin receptor activating peptide-6 induced, velocity 25±4 26±5 26±5 0.852
Thrombin receptor activating peptide-6 induced, 
aggregation
221±35 226±34 218±35 0.799
Thrombin receptor activating peptide-6 induced, AUC (U) 119±2 124±20 119±21 0.736
Ristocetin induced, velocity 30 (24–38) 30 (23–38) 31 (26–32) 0.846
Ristocetin induced, aggregation 223±49 226±43 221±52 0.951
Ristocetin induced, AUC (U) 100±28 101±26 99±32 0.963
Collagen induced, velocity 18 (17–21) 20 (17–23) 19 (16–22) 0.278
Collagen induced, aggregation 166±38 174±34 174±44 0.762
Collagen induced, AUC (U) 75±18 80±18 78±21 0.658
Microparticles
CD42 (events/µL plasma) 984 (468–2043) 1216 (753–3382) 957 (633–2098) 0.327
CD61 (events/µL plasma) 539 (145–1442) 1363 (420–2368) 784 (212–1451) 0.494
CD62P (events/µL plasma) 462 (205–975) 1075 (345–2274) 615 (174–1032) 0.113
Annexin (events/µL plasma) 447 (235–811) 933 (338–1952) 704 (207–1387) 0.028
Pre, baseline values registered after 30 minutes of sitting in the centrifuge gondola; post, values registered immediately after the centrifuge had stopped; 
post+30, values registered 30 minutes after the centrifuge run. During this half hour the participants were allowed to move freely inside the centrifuge facility. 
EImax, the ratio of maximum deformability of red blood cells, SS1/2: EImax, shear stress required for one-half of EImax with lower values representing higher 
red blood cell deformability. Normal distributed values are shown as mean±SD. Nonnormal distributed values are shown as median (first–third percentile). ADP 
indicates adenosine diphosphate; AUC, area under the curve.
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concentrations tended to increase modestly after 
centrifugation (134  ng/mL, IQR, 103–226) with re-
spect to baseline (127 ng/mL, IQR, 107–215) (P=0.056) 
(Figure 3D). Thrombin-antithrombin complex, a marker 
of prothrombotic state, increased from 2.2 (IQR, 2.0–
2.2) at baseline to 2.5 ng/mL (IQR, 2.2–3.2) after hyper-
gravity (P<0.001). We observed significant influences of 
hypergravity on the intrinsic and common coagulation 
pathways. Activated partial thromboplastin time was 
reduced from 28 seconds (IQR, 26–29) to 25 seconds 
(IQR, 24–28) (P<0.001). Circulating levels of fibrinogen, 
and the activity of the accelerators of the common 
pathway coagulation factors V, VIII, and XIII increased 
with centrifugation compared with baseline (Figure 3C, 
Table  2). Soluble tissue factor, the primary trigger of 
the coagulation cascade through the extrinsic pathway 
was increased after hypergravity exposure (P=0.023) 
(Figure  3A). Plasmin-alpha2-antiplasmin complex was 
higher after centrifugation (961 ng/mL, IQR, 549–1246) 
compared with baseline (618, IQR, 476–774) (P=0.002) 
(Figure 3E).
Coagulation Inhibitors May Attenuate 
Hypercoagulability During Hyper Gravity
Neither the protein C activity nor the thrombomodulin 
concentration were affected by hypergravity. In con-
trast hypergravity increased the activity of antithrom-
bin from 104±8% to 112±9% compared with baseline 
(P=0.005) (Figure 3F). Additionally, tissue-plasminogen 
activator, which is involved in breakdown of blood clots, 
was higher after hypergravity exposure compared with 
baseline (P<0.001) (Table 2).
DISCUSSION
The important finding of our study is that centrif-
ugation-induced hypergravity resembling gravity 
loads during suborbital spaceflight elicits significant 
hemostatic changes in healthy people. Hypergravity 
accelerated blood clot formation ex vivo, as indi-
cated by increased soluble tissue factor concen-
trations and modestly elevated d-dimer levels. The 
response was associated with hemoconcentration, 
platelet activation, increased microparticle formation, 
and red blood cell aggregation. However, coagula-
tion inhibitors and fibrinolytic factors increased to a 
similar degree after exposure to hypergravity and no 
participant displayed clinical signs of thromboembo-
lism. Thus, hypergravity transiently promotes a mild 
prothrombotic phenotype in healthy people, which 
should prompt adequately powered clinical studies 
on hemostasis in aviators, professional astronauts, 
and candidates for touristic spaceflight.
Following hypergravity exposure, we observed 
augmented integrated blood coagulation by throm-
belastography indicated by shortened clotting time of 
native blood. A shortening of clotting time indicates 
accelerated thrombin generation, which can be at-
tributed to an increased tissue factor expression on 
circulating cells caused by traumatic tissue destruc-
tion, inflammation,18 circulating tumor cells, or infec-
tion.19,20 Several thrombelastographic parameters 
indicate hypercoagulability, namely shortened clot-
ting time and clot formation time, increased mean clot 
firmness, and shutdown of fibrinolysis. The potency 
Figure 3. Effects of 15  minutes of 3  Gz hypergravity on 
the cellular and plasmatic components of the hemostatic 
system.
A, Black columns represent means of soluble tissue factor 
concentrations±SD before, after, and 30  minutes after 
hypergravity. Grey dotted graph represents means corrected for 
plasma volume; (B) black columns give means±SD of clotting times 
of native blood before, after, and 30 minutes after hypergravity; 
(C) medians±interquartile range (IQR) of activity percentage of 
coagulation factor VIII (F VIII) are given as black column before, 
after, and 30  minutes after hypergravity; (D) black columns 
indicate medians of d-dimer concentrations±interquartile range 
(IQR) before, after, and 30  minutes after hypergravity. Grey 
dotted graph represents medians corrected for plasma volume; 
(E) black columns show median concentrations±interquartile 
range of plasmin-alpha2-antiplasmin complex before, after, 
and 30 minutes after hypergravity exposure. Grey dotted graph 
represents medians corrected for plasma volume; (F) means±SD 
of antithrombin activity before, after, and 30  minutes after 
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of thrombelastometry to reveal hypercoagulability has 
been intensively investigated.21–23
Externalization of platelet membrane phospha-
tidylserine following hypergravity exposure, which 
likely results from the so-called flip-flop process, is 
consistent with platelet activation.24 Exposure of cell 
membrane phosphatidylserine is required for clot 
formation via vitamin-K dependent clotting factors 
and thrombin generation. Platelet-derived micro-
particles, which are formed following platelet activa-
tion, are strong procoagulants and have been linked 
with clinical thromboembolic risk.25 Although plate-
lets appeared to be activated, we did not observe 
an increase in platelet-derived microparticles with 
hypergravity.
Hypergravity induced rapid reductions in blood 
and plasma volumes by ≈7% and 13%, respectively, 
with accompanying increases in blood viscosity and 
platelet counts. Similar plasma volume changes 
occur within 1 hour standing still on Earth.1 Changes 
in coagulation measurements in our study were at-
tenuated after adjusting for plasma volume suggest-
ing that hemoconcentration may have contributed to 
the response. Indeed, hemoconcentrations has been 
implicated in altered hemostasis associated with hy-
poxia, heat exposure, and psychological, physical, or 
orthostatic stress. A procoagulatory state, exemplified 
by clotting time (Figure 3B), persisted 30 minutes after 
centrifugation while intravascular volume had recov-
ered. Moreover, hydration does not attenuate ortho-
static hypercoagulability.26 Red blood cell aggregation 
and shear forces required to separate the aggregates 
were observed even after adjusting hematocrit. The 
findings are qualitatively in line with previous findings of 
increased red blood cell aggregation after 30 minutes 
of short-arm centrifugation at +2 Gz.6 Overall, changes 
in coagulability with hypergravity may not be solely ex-
plained by hypergravity-induced changes in plasma 
volume.
Increases in tissue factor concentrations could also 
be mediated through hypergravity-driven vascular 
endothelium and monocyte activation. Activated cir-
culating monocytes account for more than 90% of sol-
uble tissue factor activity.27 Monocytes are activated 
by cyclic pressure changes via a pathway engaging 
PIEZO1 (Piezo1 channel protein) and hypoxia-induc-
ible factor proteins.28 Furthermore, endothelial cells 
are sensitive to hypergravity-induced shear forces to 
the vascular wall.7 Orthostatic stress also stimulates 
endothelial tissue factor expression, tissue plasmin-
ogen activator, and plasminogen activator inhibitor-1 
release.1 During centrifugation, our participants were 
exposed to ≈330  mm  Hg systolic arterial pressure 
at the level of the feet, which is well above the pres-
sure causing failure of endothelial barrier function.29 
A mismatch in d-dimers and prothrombin fragments 
F1+2 concentrations is a known phenomenon likely 
resulting from higher thrombin generation rates than 
expected by prothrombin fragment plasma levels.30,31 
The fact that the endothelial derived biomarkers 
thrombomodulin and protein C were unchanged after 
hypergravity exposure is unexpected but may be ex-
plained by the brevity of hypergravity exposure and 
the type of endothelial stress. Thrombomodulin is a 
marker for endothelial injury secondary to vascular in-
flammation rather than mechanical stress.32 Similarly, 
51 minutes of combined orthostatic and heat stress 
while promoting systemic inflammation and coagu-
lation did not affect thrombomodulin and protein C 
concentrations.33
Biomarkers for fibrinolytic activity, such as plas-
min-alpha2-antiplasmin, increased after hypergravity 
exposure indicating the fibrinolytic activation of en-
dothelial cells. Plasmin-alpha2-antiplasmin levels rep-
resent the in vivo plasmin generation.34 Tissue-type 
plasminogen activator and plasminogen activator in-
hibitor type 1 release after centrifugation points toward 
vulnerability of the fibrinolytic system to hypergravity. 
Sympathoadrenal activation, which occurs during 3 Gz 
exposures,35 is known to increase tissue plasminogen 
activator concentrations.36
Limitations
One potential limitation of our study is that we stud-
ied only young to middle-aged men although sex 
and age are relevant factors affecting hemostasis.37 
Yet, in women, oral contraception could interact with 
hypergravity-induced prothrombotic responses.38 
Because of safety concerns, we exposed our par-
ticipants to moderate hypergravity load of modest 
duration. Animal studies suggest that higher gravity 
loads, which can occur in high performance aircrafts 
and during spaceflight, may induce more pro-
nounced hemostasis.8 Because the follow-up phase 
of our study was limited to 30 minutes, we may have 
missed delayed but relevant hemostatic responses 
to hypergravity as suggested by a low though rapid 
increase of thrombin-antithrombin complex and dis-
cordant prothrombin fragments F1+2 and d-dimer re-
sponses, respectively. For comparison, the so-called 
economy class syndrome can occur hours to days 
after air travel. Moreover, we did not analyze von 
Willebrand factor in its role as a blood plasma marker 
for endothelial activation.39 Although waterfall plots 
revealed extreme individual responses in some cell-
based measurements, quantile regression analysis 
failed to uncover any concordant extreme reaction 
across several related variables. Given the limited 
sample size, we cannot exclude that subgroups with 
extreme hemostatic responses to hypergravity exist. 
Finally, although changes in intravascular volumes 
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Table 2. Hypergravity-Induced Changes of the Plasmatic Hemostasis System
Pre Post Post+30 P Value
Thrombelastography
Clotting time of native blood, s 719±117 688±104 628±89 0.038
Clot formation time of native blood, s 273±61 268±59 258±55 0.716
Mean clot firmness of native blood, mm 46±5 48±4 47±5 0.498
Extrinsic activation, clotting time, s 51 (44–54) 47 (40–56) 48 (42–54) 0.959
Extrinsic activation, clot formation time, s 102±21 98±18 102±19 0.616
Extrinsic activation, mean clot firmness, mm 55±5 57±4 55±4 0.464
Intrinsic activation, clotting time, s 162±17 153±17 157±15 0.319
Intrinsic activation, clot formation time, s 83±14 84±15 88±14 0.603
Intrinsic activation, mean clot firmness, mm 55±3 55±4 54±4 0.467
Extrinsic activation with platelet inhibition, mean clot 
firmness, mm
11 (10–13) 11 (10–14) 11 (10–13) 0.101
Inflammation/global coagulation testing
C-reactive protein, mg/dL 0.09 (0.04–0.17) 0.11 (0.04–0.18) … 0.001
0.11 (0.04–0.17)† 0.396†
Prothrombin time, % 97±13 103±13 95±11 0.173
Partial thromboplastin time, s 28 (26–29) 25 (24–28) 26 (24–28) <0.001
Procoagulation
Fibrinogen, mg/dL 303 (285–345) 315 (303–366) 301 (282–341) <0.001
275 (285–345)† 298 (282–336)† 0.016†
Tissue factor, pg/mL 188±95 298±136 263±119 0.023
270±134† 265±122† 0.076†
Coagulation factor V (%) 86 (73–91) 88 (78–101) 88 (80–95) 0.015
Coagulation factor VIII (%) 117 (93–134) 151 (133–175) 144 (127–173) <0.001
Coagulation factor XIII (%) 116 (106–159) 137 (120–167) 115 (106–163) <0.001
D-dimer, µg/L 127 (107–214) 134 (103–226) 153 (103–220) 0.056
116 (95–208)† 147 (106–225)† 0.801†
Activated protein C resistance [ratio] 2.7 (2.6–2.8) 2.7 (2.6–2.7) 2.7 (2.6–2.9) 0.617
F1,F2 prothrombin fragment, nmol/mL 0.09±0.03 0.10±0.03 0.09±0.03 0.250
0.09 (0.06–0.13)† 0.08 (0.07–0.12)† 0.513†
Thrombin-antithrombin complex, ng/mL 2.2 (2.0–2.5) 2.5 (2.2–3.2) 2.4 (2.0–2.6) <0.001
2.4 (2.0–2.8)† 2.4 (2.1–2.6)† 0.128†
Anticoagulation
Antithrombin, % 104±8 112±9 104±8 0.005
Protein C, % 98±13 106±14 98±14 0.132
Thrombomodulin, ng/mL 1.9±0.4 2.0±0.6 1.8±0.5 0.471
1.8±0.5† 1.8±0.6† 0.658†
Plasminogen activator inhibitor antigen, ng/mL 11.3 (8.1–16.6) 21.7 (19.0–34.8) 13.3 (8.7–17.1) <0.001
20.0 (17.3–32.1)† 12.9 (8.6–17.6)† <0.001†
Plasmin-α2-antiplasmin complex, ng/mL 618 (476–774) 961 (549–1246) 783 (500–950) 0.002
892 (467–1135)† 783 (492–945)† 0.024†
Tissue plasminogen activator antigen, µg/L 1.0 (0.8–1.4) 3.3 (2.7–4.5) 1.9 (1.7–2.3) <0.001
3.0 (2.5–3.8)† 1.9 (1.7–2.3)† <0.001†
Pre, baseline values registered after 30 minutes of sitting in the centrifuge gondola; post, values registered immediately after the centrifuge had stopped; 
post+30, values registered 30 minutes after the centrifuge run. During this half hour the participants were allowed to move freely inside the centrifuge facility. 
Normal distributed values are shown as mean±SD. Nonnormal distributed values are shown as median (first–third percentile).
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consensus on how to correct for such changes.40–43 
Plasma volume correction reduced the magnitude of 
alterations of parameters examined by concentration 
means. However, given nonlinear kinetics and dy-
namic interactions between coagulation factors, sim-
ple arithmetic correction for plasma volume changes 
may not suffice.
CONCLUSIONS
In healthy people, hypergravity augments blood 
coagulability within physiological limits through in-
creased red blood cell adherence, endothelial cell 
activation, increased viscoelasticity, and augmented 
platelet reactivity. For example, thrombin-antithrom-
bin complex concentrations increased only from 2.2 
to 2.5  ng/mL. The response may be partly com-
pensated by elevated levels of coagulation inhibi-
tors. Furthermore, venous pooling in the dependent 
part of the body may produce venous stasis and 
increased intravascular pressure. Thus, hypergrav-
ity affects all components of Virchow’s triad, which 
could predispose to thrombus formation (Figure  4). 
Yet, whether the modest response may increase 
thromboembolic risk in people exposed to hyper-
gravity stays highly speculative. Previous studies of 
the economy class syndrome suggested that mod-
est alterations in classical coagulation factors may 
promote thromboembolic risk.44,45 The relevance of 
this issue for governmental and touristic spaceflight 
should be pursued in further adequately powered 
studies. To uncover whether subsets of indivduals 
with extreme hemostatic responses to hypergrav-
ity exist should be a priority. Initiatives to fly tourists 
to the International Space Station and the develop-
ment of commercial spaceflight programs will lead to 
an increasing number of individuals exposed to hy-
pergravity. Only recently, the first 2 cases of venous 
thromboembolism during a space mission have been 
reported.46 To date, only ≈600 highly selected and 
trained individuals at a considerably young age have 
flown into space with no fatal thromboembolic event 
but this may lack generalizability.47 Space tourists, in 
contrast, will be less well selected, older, and less fit 
compared with professional astronauts, and a medi-
cal history of minor to moderate thromboembolic or 
cardiovascular disease will most likely not disqualify 
them from flight.
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